PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression
Open accessThe DOI matches its Crossref record; 84 of the 87 references it cites were found in a registry or an index.
Abstract
Targeted therapy with small molecules directed at essential survival pathways in leukemia represents a major advance, including the phosphatidylinositol-3'-kinase (PI3K) p110δ inhibitor idelalisib. Here, we found that genetic inactivation of p110δ (p110δD910A/D910A) in the Eμ-TCL1 murine chronic lymphocytic leukemia (CLL) model impaired B cell receptor signaling and B cell migration, and significantly delayed leukemia pathogenesis. Regardless of TCL1 expression, p110δ inactivation led to rectal prolapse in mice resembling autoimmune colitis in patients receiving idelalisib. Moreover, we showed that p110δ inactivation in the microenvironment protected against CLL and acute myeloid leukemia. After receiving higher numbers of TCL1 leukemia cells, half of p110δD910A/D910A mice spontaneously recovered from high disease burden and resisted leukemia rechallenge. Despite disease resistance, p110δD910A/D910A mice exhibited compromised CD4+ and CD8+ T cell response, and depletion of CD4+ or CD8+ T cells restored leukemia. Interestingly, p110δD910A/D910A mice showed significantly impaired Treg expansion that associated with disease clearance. Reconstitution of p110δD910A/D910A mice with p110δWT/WT Tregs reversed leukemia resistance. Our findings suggest that p110δ inhibitors may have direct antileukemic and indirect immune-activating effects, further supporting that p110δ blockade may have a broader immune-modulatory role in types of leukemia that are not sensitive to p110δ inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mice bearing an inactivating mutation in Pik3cd exhibit superior resistance to chronic lymphocytic leukemia (CLL) in the context of impaired TREG cell expansion (Dong et al., 2019; Hanna et al., 2019)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Dong et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
The microbiota in adaptive immune homeostasis and disease
Honda, K., & Littman, D. R. (2016) · Nature · doi:10.1038/nature18848 · Cited by 1,846
Dysbiosis and the immune system
Levy, M., Kolodziejczyk, A. A., Thaiss, C. A., & Elinav, E. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.7 · Cited by 1,769
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A., & Wargo, J. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.015 · Cited by 1,392
‘Acute myeloid leukemia: a comprehensive review and 2016 update’
De Kouchkovsky, I., & Abdul-Hay, M. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.50 · Cited by 1,317
Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice
Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S. E., Salpekar, A., Waterfield, M. D., et al. (2002) · Science · doi:10.1126/science.1073560 · Cited by 946
Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810
Self-citationAnalysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation
Fabbri, G., Rasi, S., Rossi, D., Trifonov, V., Khiabanian, H., Ma, J., Grunn, A., Fangazio, M., Capello, D., Monti, S., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110921 · Cited by 610
Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape
Mohme, M., Riethdorf, S., & Pantel, K. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.144 · Cited by 602
Ramsay, A. G., Johnson, A. J., Lee, A. M., Gorgün, G., Le Dieu, R., Blum, W., Byrd, J. C., & Gribben, J. G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35017 · Cited by 600
Self-citationHuman chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression
Bichi, R., Shinton, S. A., Martin, E. S., Koval, A., Calin, G. A., Cesari, R., Russo, G., Hardy, R. R., & Croce, C. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.102181599 · Cited by 582
Normalization of host intestinal mucus layers requires long-term microbial colonization
Johansson, M. E. V., Jakobsson, H. E., Holmén-Larsson, J., Schütte, A., Ermund, A., Rodríguez-Piñeiro, A. M., Arike, L., Wising, C., Svensson, F., Bäckhed, F., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.10.007 · Cited by 549
Hoellenriegel, J., Meadows, S. A., Sivina, M., Wierda, W. G., Kantarjian, H., Keating, M. J., Giese, N., O'Brien, S., Yu, A., Miller, L. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-352492 · Cited by 549
Herman, S. E. M., Gordon, A. L., Wagner, A. J., Heerema, N. A., Zhao, W., Flynn, J. M., Jones, J., Andritsos, L., Puri, K. D., Lannutti, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271171 · Cited by 543
Self-citationInactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Ali, K., Soond, D. R., Piñeiro, R., Hagemann, T., Pearce, W., Lim, E. L., Bouabe, H., Scudamore, C. L., Hancox, T., Maecker, H., et al. (2014) · Nature · doi:10.1038/nature13444 · Cited by 529
Riches, J. C., Davies, J. K., McClanahan, F., Fatah, R., Iqbal, S., Agrawal, S., Ramsay, A. G., & Gribben, J. G. (2013) · Blood · doi:10.1182/blood-2012-09-457531 · Cited by 529
Kipps, T. J., Stevenson, F. K., Wu, C. J., Croce, C. M., Packham, G., Wierda, W. G., O'Brien, S., Gribben, J., & Rai, K. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.96 · Cited by 517
Beyer, M., Kochanek, M., Darabi, K., Popov, A., Jensen, M., Endl, E., Knolle, P. A., Thomas, R. K., von Bergwelt-Baildon, M., Debey, S., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0642 · Cited by 492
Clayton, E., Bardi, G., Bell, S. E., Chantry, D., Downes, C. P., Gray, A., Humphries, L. A., Rawlings, D., Reynolds, H., Vigorito, E., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020805 · Cited by 446
Yu, P., Lee, Y., Liu, W., Krausz, T., Chong, A., Schreiber, H., & Fu, Y.-X. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041684 · Cited by 432
Yuan, R., Tsaih, S., Petkova, S. B., De Evsikova, C. M., Xing, S., Marion, M. A., Bogue, M. A., Mills, K. D., Peters, L. L., Bult, C. J., et al. (2009) · Aging Cell · doi:10.1111/j.1474-9726.2009.00478.x · Cited by 411
Ibrutinib treatment improves T cell number and function in CLL patients
Long, M., Beckwith, K., Do, P., Mundy, B. L., Gordon, A., Lehman, A. M., Maddocks, K. J., Cheney, C., Jones, J. A., Flynn, J. M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89756 · Cited by 388
Self-citationp110δ, a novel phosphoinositide 3-kinase in leukocytes
Vanhaesebroeck, B., Welham, M. J., Kotani, K., Stein, R., Warne, P. H., Zvelebil, M. J., Higashi, K., Volinia, S., Downward, J., & Waterfield, M. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4330 · Cited by 376
Jou, S.-T., Carpino, N., Takahashi, Y., Piekorz, R., Chao, J.-R., Carpino, N., Wang, D., & Ihle, J. N. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.24.8580-8591.2002 · Cited by 357
Burger, J. A., Quiroga, M. P., Hartmann, E., Bürkle, A., Wierda, W. G., Keating, M. J., & Rosenwald, A. (2009) · Blood · doi:10.1182/blood-2008-07-170415 · Cited by 330
Tcl1 enhances Akt kinase activity and mediates its nuclear translocation
Pekarsky, Y., Koval, A., Hallas, C., Bichi, R., Tresini, M., Malstrom, S., Russo, G., Tsichlis, P., & Croce, C. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3028 · Cited by 310
Patton, D. T., Garden, O. A., Pearce, W. P., Clough, L. E., Monk, C. R., Leung, E., Rowan, W. C., Sancho, S., Walker, L. S. K., Vanhaesebroeck, B., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6598 · Cited by 303
Szczepanski, M. J., Szajnik, M., Czystowska, M., Mandapathil, M., Strauss, L., Welsh, A., Foon, K. A., Whiteside, T. L., & Boyiadzis, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3010 · Cited by 303
Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells
Görgün, G., Holderried, T. A. W., Zahrieh, D., Neuberg, D., & Gribben, J. G. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24176 · Cited by 298
Zhou, Q., Munger, M. E., Highfill, S. L., Tolar, J., Weigel, B. J., Riddle, M., Sharpe, A. H., Vallera, D. A., Azuma, M., Levine, B. L., et al. (2010) · Blood · doi:10.1182/blood-2010-03-275446 · Cited by 287
Lampson, B. L., Kasar, S. N., Matos, T. R., Morgan, E. A., Rassenti, L., Davids, M. S., Fisher, D. C., Freedman, A. S., Jacobson, C. A., Armand, P., et al. (2016) · Blood · doi:10.1182/blood-2016-03-707133 · Cited by 285
Self-citationGhia, P., Strola, G., Granziero, L., Geuna, M., Guida, G., Sallusto, F., Ruffing, N., Montagna, L., Piccoli, P., Chilosi, M., et al. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200205)32:5<1403::aid-immu1403>3.0.co;2-y · Cited by 271
Regulatory T cells and treatment of cancer
Curiel, T. J. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.04.008 · Cited by 262
Chantry, D., Vojtek, A., Kashishian, A., Holtzman, D. A., Wood, C., Gray, P. W., Cooper, J. A., & Hoekstra, M. F. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.31.19236 · Cited by 253
Flinn, I. W., O’Brien, S., Kahl, B., Patel, M., Oki, Y., Foss, F. F., Porcu, P., Jones, J., Burger, J. A., Jain, N., et al. (2018) · Blood · doi:10.1182/blood-2017-05-786566 · Cited by 252
Jitschin, R., Braun, M., Büttner, M., Dettmer-Wilde, K., Bricks, J., Berger, J., Eckart, M. J., Krause, S. W., Oefner, P. J., Le Blanc, K., et al. (2014) · Blood · doi:10.1182/blood-2013-12-546416 · Cited by 251
Ringshausen, I., Schneller, F., Bogner, C., Hipp, S., Duyster, J., Peschel, C., & Decker, T. (2002) · Blood · doi:10.1182/blood-2002-02-0539 · Cited by 248
Sujobert, P. (2005) · Blood · doi:10.1182/blood-2004-08-3225 · Cited by 245
Reif, K., Okkenhaug, K., Sasaki, T., Penninger, J. M., Vanhaesebroeck, B., & Cyster, J. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2236 · Cited by 230
Casamayor-Palleja, M., Khan, M., & MacLennan, I. C. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.4.1293 · Cited by 226
Woyach, J. A., Bojnik, E., Ruppert, A. S., Stefanovski, M. R., Goettl, V. M., Smucker, K. A., Smith, L. L., Dubovsky, J. A., Towns, W. H., MacMurray, J., et al. (2014) · Blood · doi:10.1182/blood-2013-07-515361 · Cited by 220
Self-citationSpiljar, M., Merkler, D., & Trajkovski, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01353 · Cited by 219
Okkenhaug, K., Patton, D. T., Bilancio, A., Garçon, F., Rowan, W. C., & Vanhaesebroeck, B. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.8.5122 · Cited by 205
Stiff, A., Trikha, P., Wesolowski, R., Kendra, K., Hsu, V., Uppati, S., McMichael, E., Duggan, M., Campbell, A., Keller, K., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1490 · Cited by 188
Self-citationRuella, M., Kenderian, S. S., Shestova, O., Fraietta, J. A., Qayyum, S., Zhang, Q., Maus, M. V., Liu, X., Nunez-Cruz, S., Klichinsky, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1527 · Cited by 188
Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia
Burger, J. A. (2011) · Hematology · doi:10.1182/asheducation-2011.1.96 · Cited by 181
Balakrishnan, K., Peluso, M., Fu, M., Rosin, N. Y., Burger, J. A., Wierda, W. G., Keating, M. J., Faia, K., O'Brien, S., Kutok, J. L., et al. (2015) · Leukemia · doi:10.1038/leu.2015.105 · Cited by 166
Lutzny, G., Kocher, T., Schmidt-Supprian, M., Rudelius, M., Klein-Hitpass, L., Finch, A. J., Dürig, J., Wagner, M., Haferlach, C., Kohlmann, A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.003 · Cited by 156
Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals
Lapalombella, R., Yeh, Y.-Y., Wang, L., Ramanunni, A., Rafiq, S., Jha, S., Staubli, J., Lucas, D. M., Mani, R., Herman, S. E. M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.040 · Cited by 140
Self-citationPascutti, M. F., Jak, M., Tromp, J. M., Derks, I. A. M., Remmerswaal, E. B. M., Thijssen, R., van Attekum, M. H. A., van Bochove, G. G., Luijks, D. M., Pals, S. T., et al. (2013) · Blood · doi:10.1182/blood-2012-11-467670 · Cited by 139
Ramsay, A. G., Evans, R., Kiaii, S., Svensson, L., Hogg, N., & Gribben, J. G. (2013) · Blood · doi:10.1182/blood-2012-08-448332 · Cited by 135
Gorgun, G., Ramsay, A. G., Holderried, T. A. W., Zahrieh, D., Le Dieu, R., Liu, F., Quackenbush, J., Croce, C. M., & Gribben, J. G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901166106 · Cited by 128
Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia
Giannopoulos, K. (1994) · Oncology Reports · doi:10.3892/or_00000059 · Cited by 124
Kondo, K., Shaim, H., Thompson, P. A., Burger, J. A., Keating, M., Estrov, Z., Harris, D., Kim, E., Ferrajoli, A., Daher, M., et al. (2018) · Leukemia · doi:10.1038/leu.2017.304 · Cited by 119
Maffei, R., Bulgarelli, J., Fiorcari, S., Bertoncelli, L., Martinelli, S., Guarnotta, C., Castelli, I., Deaglio, S., Debbia, G., De Biasi, S., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.073080 · Cited by 116
McClanahan, F., Riches, J. C., Miller, S., Day, W. P., Kotsiou, E., Neuberg, D., Croce, C. M., Capasso, M., & Gribben, J. G. (2015) · Blood · doi:10.1182/blood-2015-02-626754 · Cited by 114
Inactivation of PI3Kγ and PI3Kδ distorts T-cell development and causes multiple organ inflammation
Ji, H., Rintelen, F., Waltzinger, C., Bertschy Meier, D., Bilancio, A., Pearce, W., Hirsch, E., Wymann, M. P., Rückle, T., Camps, M., et al. (2007) · Blood · doi:10.1182/blood-2007-04-086751 · Cited by 114
Johnson, A. J., Lucas, D. M., Muthusamy, N., Smith, L. L., Edwards, R. B., De Lay, M. D., Croce, C. M., Grever, M. R., & Byrd, J. C. (2006) · Blood · doi:10.1182/blood-2005-12-011213 · Cited by 111
Self-citationHofbauer, J. P., Heyder, C., Denk, U., Köcher, T., Holler, C., Trapin, D., Asslaber, D., Tinhofer, I., Greil, R., & Egle, A. (2011) · Leukemia · doi:10.1038/leu.2011.111 · Cited by 102
Guo, H., Samarakoon, A., Vanhaesebroeck, B., & Malarkannan, S. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072327 · Cited by 101
Nguyen, P., Fedorchenko, O., Rosen, N., Koch, M., Barthel, R., Winarski, T., Florin, A., Wunderlich, F. T., Reinart, N., & Hallek, M. J. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.007 · Cited by 99
Fiorcari, S., Brown, W. S., McIntyre, B. W., Estrov, Z. E., Maffei, R., O'Brien, S. M., Sivina, M., Hoellenriegel, J., Wierda, W. G., Keating, M. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083830 · Cited by 98
ROR1 can interact with TCL1 and enhance leukemogenesis in Eµ-TCL1 transgenic mice
Widhopf, G. F., Cui, B., Ghia, E. M., Chen, L., Messer, K. S., Shen, Z., Briggs, S. P., Croce, C. M., & Kipps, T. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308374111 · Cited by 96
Kim, N., Saudemont, A., Webb, L., Camps, M., Ruckle, T., Hirsch, E., Turner, M., & Colucci, F. (2007) · Blood · doi:10.1182/blood-2007-02-075366 · Cited by 93
PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells
Bowers, J. S., Majchrzak, K., Nelson, M. H., Aksoy, B. A., Wyatt, M. M., Smith, A. S., Bailey, S. R., Neal, L. R., Hammerbacher, J., & Paulos, C. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01221 · Cited by 91
Uno, J. K., Rao, K. N., Matsuoka, K., Sheikh, S. Z., Kobayashi, T., Li, F., Steinbach, E. C., Sepulveda, A. R., Vanhaesebroeck, B., Sartor, R. B., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.07.008 · Cited by 83
Holler, C., Hofbauer, J. P., Denk, U., Heyder, C., Hofbauer, S. W., Greil, R., & Egle, A. (2009) · Blood · doi:10.1182/blood-2008-06-160713 · Cited by 82
PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)
Okkenhaug, K., & Burger, J. A. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_484 · Cited by 78
Goolsby, C. L., Kuchnio, M., Finn, W. G., & Peterson, L. C. (2000) · Cytometry · doi:10.1002/1097-0320(20000615)42:3<188::aid-cyto5>3.0.co;2-q · Cited by 75
den Hove, L. E. V., Vandenberghe, P., Gool, S. W. V., Ceuppens, J. L., Demuynck, H., Verhoef, G. E. G., & Boogaerts, M. (1998) · Leukemia Research · doi:10.1016/s0145-2126(97)00152-5 · Cited by 73
Molecular Pathways: Targeting Phosphoinositide 3-Kinase p110-Delta in Chronic Lymphocytic Leukemia
Herman, S. E. M., & Johnson, A. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1402 · Cited by 55
Self-citationGassner, F. J., Zaborsky, N., Catakovic, K., Rebhandl, S., Huemer, M., Egle, A., Hartmann, T. N., Greil, R., & Geisberger, R. (2015) · British Journal of Haematology · doi:10.1111/bjh.13467 · Cited by 52
Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies
Gaudio, E., Spizzo, R., Paduano, F., Luo, Z., Efanov, A. A., Palamarchuk, A., Leber, A. S., Kaou, M., Zanesi, N., Bottoni, A., et al. (2011) · Blood · doi:10.1182/blood-2011-08-374561 · Cited by 52
Innate PI3K p110δ Regulates Th1/Th17 Development and Microbiota-Dependent Colitis
Steinbach, E. C., Kobayashi, T., Russo, S. M., Sheikh, S. Z., Gipson, G. R., Kennedy, S. T., Uno, J. K., Mishima, Y., Borst, L. B., Liu, B., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301533 · Cited by 52
Göthert, J. R., Eisele, L., Klein‐Hitpaß, L., Weber, S., Zesewitz, M.-L., Sellmann, L., Röth, A., Pircher, H., Dührsen, U., & Dürig, J. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1473-z · Cited by 49
Liu, D., & Uzonna, J. E. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903177 · Cited by 39
Zucchetto, A., Tripodo, C., Benedetti, D., Deaglio, S., Gaïdano, G., Poeta, G. D., & Gattei, V. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08152.x · Cited by 38
Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia
Purroy, N., & Wu, C. J. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026740 · Cited by 33
Epigenetic alterations in a murine model for chronic lymphocytic leukemia
Chen, S., Sherman, M. H., Hertlein, E. K., Johnson, A. J., Teitell, M. A., Byrd, J. C., & Plass, C. (2009) · Cell Cycle · doi:10.4161/cc.8.22.9957 · Cited by 26
Self-citationNganga, V. K., Palmer, V., Naushad, H., Kassmeier, M. D., Anderson, D. K., Perry, G. A., Schabla, N. M., & Swanson, P. C. (2013) · Blood · doi:10.1182/blood-2012-08-446732 · Cited by 25
Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials.
Coutre, S. E., Barrientos, J. C., Brown, J. R., de Vos, S., Furman, R. R., Keating, M. J., O'Brien, S. M., Pagel, J. M., Sharman, J. P., Zelenetz, A. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.e18030 · Cited by 18
Self-citationKöcher, T., Asslaber, D., Zaborsky, N., Flenady, S., Denk, U., Reinthaler, P., Ablinger, M., Geisberger, R., Bauer, J., Seiffert, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.307 · Cited by 16
Hock, B. D., MacPherson, S. A., & McKenzie, J. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172858 · Cited by 9
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Self-citationPI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 476
Self-citationYan, Y., Huang, L., Liu, Y., Yi, M., Chu, Q., Jiao, D., & Wu, K. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01322-3 · Cited by 212
“Since the participation of PI3K-p110δ in promoting Treg migration has been extensively studied, PI3K p110δ antagonists, such as idelalisib, have been broadly applied as immune modulators to treat hematologic malignancies [113].”
BackgroundImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
Roessner, P. M., & Seiffert, M. (2020) · Leukemia · doi:10.1038/s41375-020-0873-2 · Cited by 144
“inhibitors which contributes to such adverse events [32, 96, 97].”
Background
Metadata
- Authors
- Dong, S., Harrington, B. K., Hu, E. Y., Greene, J. T., Lehman, A. M., Tran, M., Wasmuth, R. L., Long, M., Muthusamy, N., Brown, J. R., Johnson, A. J., & Byrd, J. C.
- Affiliations
- The Ohio State University (US)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Johnson, Amy J.
- Byrd, John C.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-11-19
- Volume
- 129
- Issue
- 1
- Pages
- 122-136
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6307940
- OpenAlex
- W2900480369
- Cited by
- 52
- References
- 87
- Citations by year
- 2025: 4 · 2024: 5 · 2023: 10 · 2022: 6 · 2021: 6 · 2020: 15 · 2019: 6
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA159296)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- PI3K p110δ, chronic lymphocytic leukemia, idelalisib, T cell suppression, regulatory T cells, B cell receptor signaling, B cell migration, acute myeloid leukemia, rectal prolapse, autoimmune colitis, tumor microenvironment, TCL1, leukemia resistance, immunomodulation
- MeSH terms
- Animals, Enzyme Activation, Immune Tolerance, Leukemia, Lymphoid, Mice, Transgenic, Neoplasms, Experimental, CD8-Positive T-Lymphocytes, Amino Acid Substitution, Mutation, Missense, T-Lymphocytes, Regulatory, Mice, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.